内皮祖细胞介导的胞嘧啶脱氨酶与内皮抑素融合基因对肝癌的基因治疗

Gene Therapy with Cytosine Deaminase and Endostatin Fusion Gene Mediated by Endothelial Progenitor Cells in Hepatomas.

作者信息

Zhang Yue-Lin, Zhou Tan-Yang, Ai Jing, Chen Sheng-Qun, Chen Feng, Nie Chun-Hui, Chen Xin-Hua, Zhou Guan-Hui, Wang Hong-Liang, Zhu Tong-Yin, Wang Bao-Quan, Yu Zi-Niu, Jing Li, Wu Li-Ming, Zheng Shu-Sen, Sun Jun-Hui

机构信息

Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, People's Republic of China.

Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, Zhejiang Province, People's Republic of China.

出版信息

Cancer Manag Res. 2020 Apr 30;12:3023-3031. doi: 10.2147/CMAR.S245998. eCollection 2020.

DOI:10.2147/CMAR.S245998

PMID:32431545

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7198450/

Abstract

PURPOSE

Gene-targeting therapy provides a novel therapeutic approach for tumor treatment using genetically modified endothelial progenitor cells (EPCs) as cellular carriers. This study applied EPCs armed with cytosine deaminase (CD) and endostatin (ES) fusion gene in liver cancer to explore its therapeutic effect.

MATERIALS AND METHODS

EPCs from heart blood of male BALB/c nude mice were cultured and transfected with CD and ES fusion gene. Subsequently, these genetically modified cells were injected into mice bearing hepatoma through their tail veins. The tumor volumes and cell apoptosis were followed up.

RESULTS

Tumor volume in the group injected CD/ES-EPCs greatly decreased. The positive rate of VEGF and CD31 in the tumor tissue was lowest in the CD/ES-EPC group. Furthermore, the number of apoptotic cells was highest in the CD/ES-EPC group.

CONCLUSION

The EPCs transfected with CD/ES inhibited tumor growth and preferentially induced tumor cell apoptosis, providing a novel methodology for cancer-targeting therapy.

摘要